These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19496282)

  • 21. Haematological malignancies: at the forefront of immunotherapeutic innovation.
    Bachireddy P; Burkhardt UE; Rajasagi M; Wu CJ
    Nat Rev Cancer; 2015 Apr; 15(4):201-15. PubMed ID: 25786696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and pathogenesis of thrombosis in hematologic malignancies.
    Kwaan HC; Vicuna B
    Semin Thromb Hemost; 2007 Jun; 33(4):303-12. PubMed ID: 17525887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guest editorial: Immunotherapy for hematological malignancies: the quest to overcome tolerogenic drive.
    Kadowaki N
    Int J Hematol; 2014 Feb; 99(2):105-6. PubMed ID: 24395282
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccination as Immunotherapy in Hematologic Malignancies.
    Liegel J; Weinstock M; Rosenblatt J; Avigan D
    J Clin Oncol; 2021 Feb; 39(5):433-443. PubMed ID: 33434056
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunotherapy for hematological cancer. Where are we?
    Borbolla JR; López-Hernández MA
    Arch Med Res; 1997; 28(4):597-8. PubMed ID: 9428591
    [No Abstract]   [Full Text] [Related]  

  • 26. Venous thromboembolism in the hematologic malignancies.
    Falanga A; Marchetti M
    J Clin Oncol; 2009 Oct; 27(29):4848-57. PubMed ID: 19752334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Game Changers in Treatment of Hematologic Malignancies.
    Goy A
    Oncology (Williston Park); 2019 Sep; 33(9):. PubMed ID: 31571178
    [No Abstract]   [Full Text] [Related]  

  • 28. [Monoclonal antibodies in hematologic neoplasms].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 2000 Mar; 23(3):74-6. PubMed ID: 10741070
    [No Abstract]   [Full Text] [Related]  

  • 29. Interleukin-2 in the treatment of hematologic malignancies.
    Fefer A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S35-6. PubMed ID: 9457391
    [No Abstract]   [Full Text] [Related]  

  • 30. Features and outcomes of pediatric early T cell leukemia: King Hussein Cancer Center experience.
    Madanat F; Jaber H; Azayyat I; Kamal N; Barakat F; Al-Kayed K; Rihani R
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):126-8. PubMed ID: 26420052
    [No Abstract]   [Full Text] [Related]  

  • 31. Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.
    Di Martino MT; Zazzeroni F; Donadelli M; Chiodoni C; Caraglia M; Scotlandi K; Meschini S; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):48. PubMed ID: 29506548
    [No Abstract]   [Full Text] [Related]  

  • 32. The transfusion tether: Bridging the gap between end-stage hematologic malignancies and optimal end-of-life care.
    Mannis GN; McNey LM; Gupta NK; Gross DM
    Am J Hematol; 2016 Jun; 91(4):364-5. PubMed ID: 26799788
    [No Abstract]   [Full Text] [Related]  

  • 33. Interleukin-2 and its receptor in adult T cell leukemia.
    Uchiyama T
    Jpn J Med; 1991; 30(6):602-6. PubMed ID: 1798225
    [No Abstract]   [Full Text] [Related]  

  • 34. [Active immunotherapy in patients with hematologic and solid neoplasms].
    Mellstedt H; Veelken H
    Onkologie; 2005 Oct; 28 Suppl 4():4-8. PubMed ID: 16285039
    [No Abstract]   [Full Text] [Related]  

  • 35. [Various mechanisms of cell death in hematological malignancies].
    Adachi S
    Rinsho Ketsueki; 2008 Aug; 49(8):650-7. PubMed ID: 18800615
    [No Abstract]   [Full Text] [Related]  

  • 36. [Epithelial stem cell and cancer].
    Taipale J
    Duodecim; 2004; 120(4):373-5. PubMed ID: 15065454
    [No Abstract]   [Full Text] [Related]  

  • 37. Guest editorial: Connecting multiple aspects of hematologic malignancies toward creation of new therapeutics.
    Ishikawa F
    Int J Hematol; 2017 May; 105(5):547-548. PubMed ID: 28233193
    [No Abstract]   [Full Text] [Related]  

  • 38. Future strategies toward the cure of indolent B-cell malignancies: introduction.
    Cheson BD
    Semin Hematol; 1999 Oct; 36(4 Suppl 5):1-2. PubMed ID: 10528908
    [No Abstract]   [Full Text] [Related]  

  • 39. Hematologic malignancies.
    Bernstein I
    Curr Opin Hematol; 1999 Jul; 6(4):199-200. PubMed ID: 10400366
    [No Abstract]   [Full Text] [Related]  

  • 40. Managed care considerations: hematologic cancer as a chronic disease.
    DePue RJ
    Manag Care; 2008 Jul; 17(7 Suppl 6):preceding table of contents. PubMed ID: 19119536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.